GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry.
market analysis
Just as Seattle Children’s Hospital (SCH) has initiated a study of two CAR-T cell therapies in young people with relapsed or refractory (R/R) non-central nervous system epidermal growth factor receptor (EGFR)-positive solid tumours, GlobalData states that if study data are positive, collaboration with industry will be required to support further clinical development and commercialisation.